Novo Nordisk Rebrands to 'Novo', Stock Falls as It Pivots to Consumer Market

On Monday, Novo Nordisk (NVO) said it will now be known simply as "Novo," unveiling a new corporate culture as the Danish drugmaker seeks to reduce the gap with rival Eli Lilly in the obesity drug market.

The rebrand and cultural shift are part of a single initiative to adapt the company's strategy, CEO Mike Doustdar told CNBC.

Strategy Behind the Shift

Doustdar said the company's operating environment has changed as obesity treatment moved from a stable, insulin-like market to one that behaves more like a consumer market, where patients cycle on and off drugs.

The new culture, called "The Novo Way," is built on four principles: customer obsession, competitiveness, clarity, and care and integrity. Doustdar noted that speed only helps once priorities are clear, and that the company still has work to do in research, manufacturing, and sales.

As part of the rebrand, the direction of Novo’s centuries-old Apis bull logo has been reversed, symbolizing a change in course while preserving heritage. The legal name remains Novo Nordisk A/S.

Stock Reaction

The announcement did not impress investors. Novo shares traded around $43.45 on Monday, down approximately 15.8% year-to-date and roughly 21% lower over the past year. The stock has fallen more than 60% from its 2024 peak near $147, when Novo led the GLP-1 race.

BMO analysts noted that the strong launch of Novo’s oral Wegovy pill this year does not by itself indicate a turnaround. Doustdar pointed to early Medicare uptake among obesity patients as an encouraging, though still preliminary, signal for demand.

“The street and the market is always right, but with a lag.”

— Mike Doustdar, CNBC

Doustdar said that sustained execution should eventually restore investor trust. The company continues to work to defend its lead over Eli Lilly’s competing oral pill.